Evidence map›Paper›PMID 34525119›Full record

ArticlePloS one2021

Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project.

Monia Ezzalfani, Raphaël Porcher, Alexia Savignoni, Suzette Delaloge, Thomas Filleron, Mathieu Robain, David Pérol, ESME Group

Registry-linked trialAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03275311 (Epidemiological Strategy and Medical Economic), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03275311 recruitingnot on this map

Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008

TypeobservationalSponsorUNICANCERRan2014 to 2027Enrolled42,000ConditionsMetastatic Breast Cancer
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Monia EzzalfaniDepartment of Biostatistics, Pôle de Biometrie, Institut Curie, Paris, France.ORCID 0000-0002-2062-7041
Raphaël PorcherUniversité de Paris, Centre of Research Epidemiology and Statistics, INSERM U1153, Paris, France.
Alexia SavignoniDepartment of Biostatistics, Pôle de Biometrie, Institut Curie, Paris, France.
Suzette DelalogeDepartment of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.
Thomas FilleronBiostatistics unit, IUCT Oncopole, Toulouse, France.ORCID 0000-0003-0724-0659
Mathieu RobainDepartment of Research and Development, R&D Unicancer, Paris, France.
David PérolDepartment of Biostatistics, DRCI, Centre Leon Berard, Lyon, France.
ESME Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeObservational studies using routinely collected data are faced with a number of potential shortcomings that can bias their results. Many methods rely on controlling for measured and unmeasured confounders. In this work, we investigate the use of instrumental variables (IV) and quasi-trial analysis to control for unmeasured confounders in the context of a study based on the retrospective Epidemiological Strategy and Medical Economics (ESME) database, which compared overall survival (OS) with paclitaxel plus bevacizumab or paclitaxel alone as first-line treatment in patients with HER2-negative metastatic breast cancer (MBC). PATIENTS AND

methodsCausal interpretations and estimates can be made from observation data using IV and quasi-trial analysis. Quasi-trial analysis has the same conceptual basis as IV, however, instead of using IV in the analysis, a "superficial" or "pseudo" randomized trial is used in a Cox model. For instance, in a multicenter trial, instead of using the treatment variable, quasi-trial analysis can consider the treatment preference in each center, which can be informative, and then comparisons of results between centers or clinicians can be informative.

resultsIn the original analysis, the OS adjusted for major factors was significantly longer with paclitaxel and bevacizumab than with paclitaxel alone. Using the center-treatment preference as an instrument yielded to concordant results. For the quasi-trial analysis, a Cox model was used, adjusted on all factors initially used. The results consolidate those obtained with a conventional multivariate Cox model.

conclusionUnmeasured confounding is a major concern in observational studies, and IV or quasi-trial analysis can be helpful to complement analysis of studies of this nature.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabBreast NeoplasmsFemaleHumansNon-Randomized Controlled Trials as TopicObservational Studies as TopicPaclitaxelPrognosisRandom AllocationRetrospective StudiesSurvival RateBevacizumabPaclitaxel

Identifiers

PMID34525119
PMCPMC8443058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.